Abstract
Recent developments in chemotherapy have improved the prognosis of patients with cancer. However, affected patients may still experience long-term chemotherapy-induced complications. We herein report a case that developed myelodysplastic syndrome (MDS) after undergoing long-term chemotherapy for ovarian cancer. A 72-year-old female (gravida 1, para 1) diagnosed with ovarian cancer was treated with total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy, and partial omentectomy. The histopathological diagnosis was ovarian serous carcinoma of stage IIC. The patient received two courses of intraperitoneal chemotherapy and six courses of cyclophosphamide, therarubicin and carboplatin as adjuvant chemotherapy. The patient also received six courses of dose-dense TC (carboplatin and paclitaxel), and six courses involving the weekly administration of irinotecan for disease recurrence. Eleven years after the primary surgery, a blood examination revealed anemia and neutropenia under dose-dense TC therapy and a bone marrow examination showed MDS. After sixth course of dose-dense TC, however, the patient developed acute myeloid leukemia and died of sepsis and cerebral hemorrhage. [Adv Obstet Gynecol, 68 (2) , 82-87, 2016 (H28.5)]
